Adamas Pharmaceuticals (NASDAQ:ADMS) has tumbled 11.42% during the past week and has dropped 15.34% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 12.61%. Adamas Pharmaceuticals (NASDAQ:ADMS) has underperformed the index by 20.78% in the last 4 weeks. Investors should watch out for further signals and trade with caution. The stock has recorded a 20-day Moving Average of 8.36% and the 50-Day Moving Average is 25.44%.
Adamas Pharmaceuticals (NASDAQ:ADMS) rose 1.77% or 0.22 points on Friday and made its way into the gainers of the day. After trading began at $12.51 the stock was seen hitting $12.765 as a peak level and $12.07 as the lowest level. The stock ended up at $12.64. The daily volume was measured at 487,271 shares. The 52-week high of the share price is $31.84 and the 52-week low is $12.02. The company has a market cap of $271 million. The company shares have dropped 28.79% in the past 52 Weeks. On December 28, 2015 The shares registered one year high of $31.84 and one year low was seen on February 25, 2016 at $12.02. The 50-day moving average is $14.33 and the 200 day moving average is recorded at $17.34. S&P 500 has rallied 2.61% during the last 52-weeks.
Investors should note that the Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged that Lieberburg Ivan M, director of Adamas Pharmaceuticals Inc, had unloaded 3,000 shares at an average price of $16.23 in a transaction dated on December 7, 2015. The total value of the transaction was worth $48,690. Currently the company Insiders own 39.87% of Adamas Pharmaceuticals shares according to the proxy statements. Institutional Investors own 52.23% of Adamas Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -15.79%.
Many analysts have stated their opinion on the company shares. Mizuho Securities initiates coverage on Adamas Pharmaceuticals (NASDAQ:ADMS). Mizuho Securities has a Neutral rating on the shares. As per the latest report, the brokerage house announces the price target to $26 per share. The rating by the firm was issued on January 19, 2016.
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on development and commercialization of therapeutics targeting chronic disorders of central nervous systems (CNS). It is engaged in modifying pharmacokinetic (PK) profiles of approved drugs to create therapeutics for use alone and in fixed-dose combination products. It develops its lead product, ADS-5102 (amantadine hydrochloride), for a complication associated with treatment of Parkinsons disease known as levodopa induced dyskinesia, and as a treatment for one or more additional CNS indications. Its other product candidate is ADS-8704. Through a partnership with Forest Laboratories Holdings Limited, its portfolio includes two drugs commercially available in the United States: Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release and donepezil hydrochloride) and Namenda XR (memantine hydrochloride) extended release capsules.